Science Explorer Interactive view Map

TherimuneX Pharmaceuticals (United States)

Research works
8
▼ 77% vs 2013–17
Citations
171
22.2 per fractional work
Top-10% rate
0.0%
record average 16.5%
Open access
47%
world 28%

Not ranked overall: TherimuneX Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Which research topics does TherimuneX Pharmaceuticals (United States) publish most on?

By volume in 2022–2025: Sirtuins and Resveratrol in Medicine, PARP inhibition in cancer therapy and Autophagy in Disease and Therapy.

  1. 1 Sirtuins and Resveratrol in Medicine Geriatrics and Gerontology 0 works
  2. 2 PARP inhibition in cancer therapy Oncology 0 works
  3. 3 Autophagy in Disease and Therapy Epidemiology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available47.0%not open53.0%

World: 28% of research is openly available.

with international co-authors5.8%domestic only94.2%

World: 19% is written across borders.

How has TherimuneX Pharmaceuticals (United States)'s research output changed?

Output in 2018–2022 was 77% lower than in 2013–2017.

20102015
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Doylestown

All research institutions in Doylestown

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.